Phase I study of cetuximab plus U3-1565 in colorectal cancer with resistance to anti-EGFR antibody

Trial Profile

Phase I study of cetuximab plus U3-1565 in colorectal cancer with resistance to anti-EGFR antibody

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2016

At a glance

  • Drugs U3 1565 (Primary) ; Cetuximab
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 03 Aug 2014 Status changed from planning to recruiting as reported by University Hospital Medical Information Network - Japan
    • 20 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top